| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 27 |
| 1 | ADALIMUMAB | 24 |
| 2 | INFLIXIMAB | 20 |
| 3 | METHOTREXATE | 18 |
| 4 | ETANERCEPT | 17 |
| 5 | DUPILUMAB | 15 |
| 6 | RIBAVIRIN | 15 |
| 7 | CETIRIZINE HYDROCHLORIDE | 14 |
| 8 | LAMOTRIGINE | 14 |
| 9 | LAMOTIRIGINE | 12 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPINASTINE HYDROCHLORIDE | 2 | 0.0018 |
| 1 | MEFENAMIC ACID | 3 | 0.0014 |
| 2 | BARICITINIB | 4 | 0.0013 |
| 3 | PURIXAN | 1 | 0.0013 |
| 4 | LAROTRECTINIB | 1 | 0.0011 |
| 5 | ESTRIOL | 2 | 0.0011 |
| 6 | SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE | 1 | 0.0010 |
| 7 | NORETHINDRONE AND ETHINYL ESTRADIOL | 1 | 0.0009 |
| 8 | TAZAROTENE | 1 | 0.0008 |
| 9 | MOGAMULIZUMAB-KPKC | 1 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 45 |
| 1 | Corticosteroid [EPC] | 27 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 21 |
| 3 | Folate Analog Metabolic Inhibitor [EPC] | 18 |
| 4 | Anti-epileptic Agent [EPC] | 17 |
| 5 | Mood Stabilizer [EPC] | 16 |
| 6 | Aminosalicylate [EPC] | 15 |
| 7 | Interleukin-4 Receptor alpha Antagonist [EPC] | 15 |
| 8 | Nucleoside Analog Antiviral [EPC] | 15 |
| 9 | Antirheumatic Agent [EPC] | 11 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 1 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 2 | CD52-directed Cytolytic Antibody [EPC] | 7 | 0.0004 |
| 3 | Provitamin D2 Compound [EPC] | 8 | 0.0003 |
| 4 | Sulfonamide Antibacterial [EPC] | 1 | 0.0003 |
| 5 | Dipeptidyl Peptidase 4 Inhibitor [EPC] | 8 | 0.0002 |
| 6 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 3 | 0.0002 |
| 7 | Hedgehog Pathway Inhibitor [EPC] | 2 | 0.0002 |
| 8 | Nucleoside Analog Antiviral [EPC] | 15 | 0.0002 |
| 9 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 2 | 0.0002 |